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Aim. Determination of the influence of Glu- and Lys-plasminogen/ plasmin on the platelet aggregation induced
by different agonists. Methods. Platelet aggregometry. Spectrophotometry. Results. We have shown the
inhibitory effect of Lys-plasminogen on human platelet ag- gregation. The pro-enzyme action is related to the
second wave of aggregation. The inhibitory effect of Lys-plasminogen possesses dose-dependent manner in case
of thrombin-induced aggregation. The inhibitory effect of pro-enzyme with ristocetin as an inductor has not been
observed. Glu-plasminogen and plasmin do not influence on platelet aggregation under studied conditions. A
serine protease inhibitor aprotinin does not change the inhibitory effect of Lys-plasminogen. Conclusions. The
results proved the inhibitory effect of Lys-plasminogen on thrombin- and collagen-induced platelet aggregation.
The absence of inhibitory effect of Lys-plasminogen in the case of ristocetin-induced aggregation leads us to
conclusion, that GP Ib/IX is not involved into the inhibited aggregation pathway. The unchanged inhibitory
effect of Lys-plasminogen in the presence of aprotinin excludes plasmin partici- pation in the inhibitory
phenomenon.
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Introduction. Plasminogen/plasmin system parti-
cipates in many physiological and pathogenic pro-
cesses, including fibrinolysis, inflammation and onco-
genesis [1, 2]. Plasminogen can interact with blood
cells, and platelets demonstrate the highest ability of
binding this protein [3].
Under normal conditions the membrane of platelets
serves as a surface for the sorption of plasminogen and
tissue plasminogen activator (TPA). There is an assum-
ption that Glu-plasminogen, circulating in blood, binds
to the platelet membrane and transforms into Lys- plas-
minogen with further formation of plasmin (Fig. 1) [4].
Therefore, the active enzyme can be relatively protect-
ed from its primary inhibitor alpha-2-antiplasmin, and
the platelet surface acquires profibrinolytic properties.
It was demonstrated that the affinity of platelets is three
times higher for Lys-plasminogen compared to its Glu-
form, although the number of sites on the cell surface
for Glu- and Lys-plasminogen is almost the same
(4.1104 and 5.5104 sites per cell, respectively) [5]. The
sorption of components of plasminogen/plasmin sys-
tem on the cell surface influences the functional prope-
rties of platelets, in particular, their aggregation. The
authors of [6, 7] demonstrated that the introduction of
plasmin (1 CU/ml) to the platelet suspension leads to
the stimulation of aggregation. However, other authors
proved a decrease in the aggregation [8–10] when pla-
telets were incubated with plasmin of lower concen-
tration or of the same concentration, but under conditi-
ons of prolonged incubation period (20 min and more).
We have established that, contrary to Glu-plasmi-
nogen, Lys-plasminogen inhibits ADP-induced aggre-
gation in the preparations of platelet-rich plasma [11].
However, only the experiments with washed platelets
may confirm this effect of the proenzyme. In addition, it
is important to establish the mechanism explaining
Lys-plasminogen influence on the platelet surface.
The present work was aimed to study the effect of
components of plasminogen/plasmin system on the ag-
gregation of washed platelets, stimulated by different
agonists.
Materials and Methods. The platelet aggregation
was studied using the preparations of washed platelets,
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obtained by the modified method [12]. Native washed
platelets were isolated by stage-by-stage centrifugation
of human blood, anticoagulated by the citrate buffer
(100 mM sodium citrate, 80 mM citric acid, 110 mM
glucose) in blood/anticoagulant ratio of 9/1.
Platelet-rich plasma (PRP) was obtained by blood
centrifugation at 1000 rpm for 20 min at room tem-
perature. Then PRP was centrifuged again (1500 rpm,
20 min), platelet precipitate was resuspended in
washing buffer (20 mM HEPES, pH 6.8, 137 mM
NaCl, 4 mM KCl, 0.2 mM MgCl with 0.2 % glucose
and 0.2 % bovine serum albumin (BSA)). Cell suspen-
sion was centrifuged for the second time under the same
conditions and resuspended in the buffer, the volume of
which was 1/2 of PRP volume. The washed platelets
were kept at 37 °C.
Aggregometry was performed during the first three
hours after blood sampling using optic aggregometer
SOLAR AT-02 by the method, described in [13]. The
platelet aggregation was stimulated by thrombin (1
NIH/ml), collagen (1.25 mg/ml) and ristomycin (1.5
mg/ml). The concentration of agonists was selected
according to the recommendations of the work [14].
The aggregation process was registered for 5 min. The
number of platelets in the sample was 300–350
thousand/µl. Before the introduction of stimulator, the
samples were incubated at 37 °C for 3 min to bind the
components of plasminogen/plasmin system with the
platelet surface [3].
The aggregometry data were analyzed using the
Aggregometer 2.01 software package. The degree, time
and rate of aggregation were estimated. The prepara-
tions of Glu-, Lys-plasminogen and plasmin were ob-
tained by colleagues of Palladin Institute of Biochemi-
stry according to [15]. The preparations of collagen, ris-
tocetin and thrombin were purchased from Technology
Standard (Russian Federation). Plasmin effect was in-
hibited with an inhibitor of serine proteinase, aprotinin
– preparation "Contriven", Biopharma (Ukraine).
The amount of plasmin in Lys-plasminogen pre-
paration and the possibility of its formation in the reac-
tion mixture during the aggregation of platelets were
determined by registering amidolytic activity of the en-
zyme with chromogenic substrate S2251 (SPA Renam,
Russian Federation).
Results and Discussion. The experiments, perfor-
med on the washed platelets, revealed the inhibitory
effect of Lys-plasminogen on the thrombin- and colla-
gen-induced aggregation (Fig. 2 and 3). In both cases
the level of aggregation decreases at least by two times.
These data prove our previous investigations, which
showed that Lys-plasminogen inhibits ADP-induced
aggregation in PRP and the main effect of this proenzy-
me was observed during the second aggregation wave,
when secretion of platelet alpha-granules occurs [11].
Similar effect we have observed with washed pla-
telets during collagen-induced aggregation. The colla-
gen effect on the platelets is known to be also related to
the second aggregation wave.
Besides, we have studied Lys-plasminogen effect
on ristocetin-induced aggregation, which is realized
through the different mechanism. Ristocetin, binding
with platelet membrane, triggers the association of von
Willebrand factor with the receptor GP Ib/IX and the
following platelet activation and agglutination. We ha-
ve shown that Lys-plasminogen has not inhibited risto-
cetin-induced aggregation in the presence of autolo-
gous blood plasma as a source of von Willebrand factor
(Fig. 4). Therefore, the absence of the proenzyme effect
on ristocetin-induced aggregation indicated the speci-
ficity of Lys-plasminogen action .
We have established a dose-dependent manner of
the inhibitory effect of Lys-plasminogen during the
thrombin-induced aggregation. The most significant in-
hibitory effect of exogenous Lys-plasminogen was ob-
served at the concentration of 1.2 µM (Fig. 5). The
further increase of proenzyme concentration did not
enhance its inhibitory action.
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Plasminogen activation in solutions
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Fig. 1 The scheme of plasminogen activation (Pg)
Since the preparations of Lys-plasminogen can pos-
sess spontaneous plasmin activity, we studied the effect
of plasmin (1 nM) on thrombin-induced platelet aggre-
gation (the previous incubation with plasmin lasted 3
min). Plasmin concentration was selected according to
its content in the preparation of Lys-plasminogen. The
results of the experiment did not demonstrate any
impact of plasmin on the thrombin-induced aggrega-
tion. This outcome is in a good agreement with the data
of [16] which did not demonstrated any influence of
nanomolar concentrations of plasmin on the thrombin-
stimulated aggregation, when the incubation time did
not exceed 3 min.
Our previous experiments with PRP established
that Glu-plasminogen closed taken at the same concen-
trations as Lys-plasminogen made no influence on
ADP-induced platelet aggregation. Our experiments
with washed platelets confirmed the absence of Glu-
plasminogen influence on thrombin-induced platelet
aggregation. The absence of the inhibitory effect could
be explained by the closed conformation of Glu-plas-
minogen.
It would be interesting to establish the mechanism
of Lys-plasminogen activity. Probably, the observed
effect is conditioned by the activity of plasmin, formed
due to the activation of Lys-plasminogen on the platelet
surface (as it was stated before, the spontaneous activity
of plasmin in the preparation of Lys-plasminogen does
not affect the thrombin-induced aggregation). If it is
true, the inhibitory effect may be suppressed by the
addition of the inhibitor of serine proteinases. To test
this assumption, we have carried out a number of expe-
riments with the inhibitor of serine proteinases, apro-
tinin. It was shown that aprotinin in the concentration of
5.5 IU/ml completely inhibits the plasmin proteolytic
activity in both Lys-plasminogen preparation and incu-
bation mixture. The introduction of aprotinin (5.5
IU/ml) to the reaction mixture does not influence the
inhibitory effect of Lys-plasminogen on the thrombin-
induced aggregation of platelets (Fig. 6). It should be
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Fig. 2 The effect of Lys-plasminogen on platelet aggregation, induced
by 1 NIH/ml of thrombin: 1 – control; 2 – 1.2 µM Lys-plasminogen
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Fig. 3 The effect of Lys-plasminogen on platelet aggregation, induced
by 1.25 mg/ml collagen: 1 – control; 2 – 1.2 µM Lys-plasminogen
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Fig. 4 The effect of Lys-plasminogen on platelet aggregation, induced
by 1.5 mg/ml ristocetin: 1 – control; 2 – 1.2 µM Lys-plasminogen
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Fig. 5 The effect of Lys-plasminogen (0.15–1.2 µM) on
thrombin-induced platelet aggregation
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noted that this concentration of aprotinin does not in-
hibit the platelet aggregation. Therefore, the partici-
pation of plasmin in the realization of the inhibitory
effect of Lys-plasminogen appears impossible.
On the other hand, Lys-plasminogen may bind
some protein components – fibrinogen, thrombospon-
din and vitronectin, which are released during the se-
cretion of alpha-granules and and condition aggrega-
tion properties of activated platelets. For example, it is
known that fibrinogen forms the bonds between pla-
telets using activated integrin IIbIIIa. Although fib-
rinogen does not interact with plasminogen in plasma,
there is a suggestion that Lys-plasminogen may bind
fibrinogen, immobilized on the platelet membrane and
impede the formation of platelet aggregates. Thromb-
ospondin is secreted from the activated platelets and
remains bound to the platelet membrane due to the
presence of its specific receptor CD47. Thrombo-
spondin is known for its ability to bind plasminogen. It
was recently demonstrated that it is an important
component, influencing the efficiency of collagen- and
thrombin-induced adhesion of washed platelets [17].
There is a suggestion, that thrombospondin promotes
platelet aggregation and fibrinogen binding due to the
integrin IIbIIIa activation. And, finally, we can't
exclude a possible role of vitronectin in the observed
effect of Lys-plasminogen. Contrary to vitronectin of
plasma, vitronectin of platelets, secreted during the
activation, is a required component for efficient aggre-
gation. The animals with vitronectin-deficient platelets
did not have the second aggregation wave [18]. The
structure of vitronectin contains the sites, responsible
for binding to plasminogen. It is probable that the
blocking of these sites by exogenous Lys-plasminogen
inhibits the platelet aggregation.
However, in spite of all these speculations, the
precise mechanism of the inhibitory effect of Lys- plas-
minogen may be elucidated only after further additional
investigations.
Conclusions. It was first determined that Lys- plas-
minogen has the inhibitory effect on the aggregation of
washed platelets, stimulated by thrombin and collagen.
The absence of the proenzyme influence on ristoce-
tin-induced aggregation indicates that Lys-plasmino-
gen does not affect the aggregation through GP Ib/IX.
We established a dose-dependent manner of the
inhibitory effect of Lys-plasminogen on the platelet
aggregation. The most significant effect is observed at
the concentration of Lys-plasminogen of 1.2 µM.
Glu-plasminogen and plasmin do not influence the
platelet aggregation under experiment conditions.
The inhibition of platelet aggregation by Lys-pla-
sminogen in the presence of aprotinin makes it impo-
ssible for plasmin to participate in the realization of the
inhibitory effect of zymogene.
ß. Ì. Ðîêà-Ìîéÿ, Ä. Ä. Æåðíîñºêîâ, Ò. Â. Ãðèíåíêî
Âïëèâ ïëàçì³íîãåíó/ïëàçì³íó íà àãðåãàö³éíó
çäàòí³ñòü òðîìáîöèò³â
²íñòèòóò á³îõ³ì³¿ ³ì. Î. Â. Ïàëëàä³íà ÍÀÍ Óêðà¿íè
Âóë. Ëåîíòîâè÷à, 9, Êè¿â, Óêðà¿íà, 01601
Ðåçþìå
Ìåòà. Âèçíà÷èòè âïëèâ Ãëó- ³ Ë³ç-ôîðì ïëàçì³íîãåíó òà ïëàçì³íó
íà àãðåãàö³þ òðîìáîöèò³â, ³íäóêîâàíó ð³çíèìè àãîí³ñòàìè. Ìå-
òîäè. Àãðåãàòîìåòð³ÿ. Ñïåêòðîôîòîìåòð³ÿ. Ðåçóëüòàòè.
Îòðèìàíî äàí³ ùîäî ³íã³áóâàëüíîãî âïëèâó Ë³ç-ïëàçì³íîãåíó íà
àãðåãàö³þ â³äìèòèõ òðîìáîöèò³â ëþäèíè. Ä³þ ïðîôåðìåíòó
ñïîñòåð³ãàëè íà äðóã³é õâèë³ àãðåãàö³¿ òðîìáîöèò³â. Ïîêàçàíî äî-
çîçàëåæíèé õàðàêòåð éîãî ³íã³áóâàëüíîãî åôåêòó íà àãðåãàö³þ
òðîìáîöèò³â, ñòèìóëüîâàíèõ òðîìá³íîì. Ðèñòîì³öèí-³íäóêîâà-
íà àãðå-ãàö³ÿ íå ïðèãí³÷óºòüñÿ Ë³ç-ïëàçì³íîãåíîì. Ãëó-ïëàçì³íî-
ãåí ³ ïëàçì³í íå âïëèâàþòü íà ôóíêö³îíàëüí³ âëàñòèâîñò³ êë³òèí
çà óìîâ åêñïåðèìåíòó. ²íã³á³òîð ñåðèíîâèõ ïðîòå¿íàç àïðîòèí³í
íå âïëèâàº íà åôåêò ³íã³áóâàííÿ àãðåãàö³¿ Ë³ç-ïëàçì³íîãåíîì.
Âèñíîâêè. Âïåðøå âñòàíîâëåíî ³íã³áóâàëüíèé âïëèâ Ë³ç-ïëàçì³íî-
ãåíó íà àãðåãàö³þ òðîìáîöèò³â, ñòèìóëüîâàíèõ òðîìá³íîì ³ êî-
ëàãåíîì. Â³äñóòí³ñòü ä³¿ ïðîôåðìåíòó íà àãðåãàö³þ, ³íäóêîâàíó
ðèñòîì³öèíîì, âêàçóº íà òå, ùî Ë³ç-ïëàçì³íîãåí íå âïëèâàº íà
ëàíêó àãðåãà- ö³¿, ÿêà ðåàë³çóºòüñÿ çà ó÷àñò³ ÃÏ ²b/IX. ²íã³áóâàííÿ
Ë³ç-ïëàçì³íîãåíîì àãðåãàö³¿ òðîìáîöèò³â çà ïðèñóòíîñò³ àïðî-
òèí³íó ðîáèòü íåìîæëèâîþ ó÷àñòü ïëàçì³íó â ðåàë³çàö³¿ ³íã³áó-
âàëüíîãî åôåêòó çèìîãåíó.
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Fig. 6 The effect of aprotinin on the inhibition of thrombin-induced
platelet aggregation by Lys-plasminogen: 1 – control; 2 – platelet
aggregation in the presence of aprotinin (5.5 IU/ml); 3 –
Lys-plasminogen (1.2 µM) in the presence of aprotinin
ROKA-MOYAY. M., ZHERNOSSEKOV D. D., GRINENKO T. V.
Êëþ÷îâ³ ñëîâà: àãðåãàö³ÿ â³äìèòèõ òðîìáîöèò³â, ïëàçì³íîãåí,
ïëàçì³í.
ß. Ì. Ðîêà-Ìîéÿ, Ä. Ä. Æåðíîñåêîâ, Ò. Â. Ãðèíåíêî
Âëèÿíèå ïëàçìèíîãåíà/ïëàçìèíà íà àãðåãàöèîííûå
ñâîéñòâà òðîìáîöèòîâ
Ðåçþìå
Öåëü. Èçó÷èòü âëèÿíèå Ãëó-, Ëèç-ôîðì ïëàçìèíîãåíà è ïëàçìèíà
íà àãðåãàöèþ òðîìáîöèòîâ, èíäóöèðóåìóþ ðàçëè÷íûìè àãîíèñ-
òàìè. Ìåòîäû. Àãðåãàòîìåòðèÿ. Ñïåêòðîôîòîìåòðèÿ. Ðåçóëü-
òàòû. Ïîëó÷åíû äàííûå îá èíãèáèðóþùåì âëèÿíèè Ëèç-ïëàçìè-
íîãåíà íà àãðåãàöèþ îòìûòûõ òðîìáîöèòîâ ÷åëîâåêà. Äåéñòâèå
ïðîôåðìåíòà ïðîÿâëÿëîñü âî âðåìÿ âòîðîé âîëíû àãðåãàöèè. Ïî-
êàçàí äîçîçàâèñèìûé õàðàêòåð åãî èíãèáèðîâàíèÿ àãðåãàöèè
òðîìáîöèòîâ, ñòèìóëèðîâàííûõ òðîìáèíîì. Ðèñòîìèöèí-èíäó-
öèðîâàííàÿ àãðåãàöèÿ íå ïîäàâëÿåòñÿ Ëèç-ïëàçìèíîãåíîì. Ãëó-
ïëàçìèíîãåí è ïëàçìèí íå âëèÿþò íà ôóíêöèîíàëüíûå ñâîéñòâà
êëåòîê â óñëîâèÿõ ýêñïåðèìåíòà. Èíãèáèòîð ñåðèíîâûõ ïðîòåè-
íàç àïðîòèíèí íå èçìåíÿåò õàðàêòåðà èíãèáèðîâàíèÿ àãðåãàöèè
Ëèç-ïëàçìèíîãåíîì.Âûâîäû. Âïåðâûå óñòàíîâëåí èíãèáèðóþùèé
ýôôåêò Ëèç-ïëàçìèíîãåíà íà àãðåãàöèþ òðîìáîöèòîâ, ñòèìóëè-
ðîâàííûõ òðîìáèíîì è êîëëàãåíîì. Îòñóòñòâèå âëèÿíèÿ ïðî-
ôåðìåíòà íà ðèñòîìèöèí-èíäóöèðîâàííóþ àãðåãàöèþ óêàçûâàåò
íà òî, ÷òî Ëèç-ïëàçìèíîãåí íå äåéñòâóåò íà ïóòü àãðåãàöèè, ðå-
àëèçóåìûé ïðè ó÷àñòèè ÃÏ²b/IX. Èíãèáèðîâàíèå Ëèç-ïëàçìèíîãå-
íîì àãðåãàöèè òðîìáîöèòîâ â ïðèñóòñòâèè àïðîòèíèíà èñêëþ-
÷àåò ó÷àñòèå ïëàçìèíà â ðåàëèçàöèè èíãèáèðóþùåãî ýôôåêòà.
Êëþ÷åâûå ñëîâà: àãðåãàöèÿ îòìûòûõ òðîìáîöèòîâ, ïëàçìè-
íîãåí, ïëàçìèí.
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